Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?

Severe manifestations of COVID-19 consist of acute respiratory distress syndrome due to an initially local reaction leading to a systemic inflammatory response that results in hypoxia. Many therapeutic approaches have been attempted to reduce the clinical consequences of an excessive immune response...

Descripción completa

Detalles Bibliográficos
Autores principales: Plocque, Alexia, Mitri, Christie, Lefèvre, Charlène, Tabary, Olivier, Touqui, Lhousseine, Philippart, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743129/
https://www.ncbi.nlm.nih.gov/pubmed/36508116
http://dx.doi.org/10.1007/s40265-022-01803-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743129/
https://www.ncbi.nlm.nih.gov/pubmed/36508116
http://dx.doi.org/10.1007/s40265-022-01803-2

Ejemplares similares